This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2006 Feb 15;55(1):163-6.

doi: 10.1002/art.21702.

Infliximab-related lupus and associated valvulitis: a case report and review of the literature

Tina Chadha¹, Jesus Edward Hernandez

Affiliations

PMID: 16463396
DOI: 10.1002/art.21702

Review

Infliximab-related lupus and associated valvulitis: a case report and review of the literature

Tina Chadha et al. Arthritis Rheum. 2006.

. 2006 Feb 15;55(1):163-6.

doi: 10.1002/art.21702.

Authors

Tina Chadha¹, Jesus Edward Hernandez

Affiliation

¹ Baylor College of Medicine, One Baylor Plaza, Suite 672E, BCM 285, Houston, TX 77030, USA. tchadha@bcm.tmc.edu

PMID: 16463396
DOI: 10.1002/art.21702

No abstract available

PubMed Disclaimer

Similar articles

Infliximab induced lupus in patients with rheumatoid arthritis.
Elkayam O, Caspi D. Elkayam O, et al. Clin Exp Rheumatol. 2004 Jul-Aug;22(4):502-3. Clin Exp Rheumatol. 2004. PMID: 15301255 Review. No abstract available.
Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, Derksen RH, van Roon JA. van Rijthoven AW, et al. Rheumatology (Oxford). 2006 Oct;45(10):1317-9. doi: 10.1093/rheumatology/kel227. Epub 2006 Jul 13. Rheumatology (Oxford). 2006. PMID: 16844698 No abstract available.
Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.
Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Favalli EG, et al. Lupus. 2002;11(11):753-5. doi: 10.1191/0961203302lu236cr. Lupus. 2002. PMID: 12475006
Adalimumab-induced lupus erythematosus.
Al-Niaimi F. Al-Niaimi F. Eur J Dermatol. 2009 Jul-Aug;19(4):380. doi: 10.1684/ejd.2009.0668. Epub 2009 May 18. Eur J Dermatol. 2009. PMID: 19451046 No abstract available.
[Worsening of subacute lupus erythematosus induced by infliximab].
Vabre-Latre CM, Bayle P, Marguery MC, Gadroy A, Durand D, Bazex J. Vabre-Latre CM, et al. Ann Dermatol Venereol. 2005 Apr;132(4):349-53. doi: 10.1016/s0151-9638(05)79281-4. Ann Dermatol Venereol. 2005. PMID: 15886563 Review. French.

See all similar articles

Cited by

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME. Furst DE, et al. Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430. Ann Rheum Dis. 2007. PMID: 17934088 Free PMC article. Review. No abstract available.
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.
Stoll ML, Gotte AC. Stoll ML, et al. Biologics. 2008 Jun;2(2):229-52. doi: 10.2147/btt.s2210. Biologics. 2008. PMID: 19707357 Free PMC article.
The protection of NF-κB inhibition on kidney injury of systemic lupus erythematosus mice may be correlated with lncRNA TUG1.
Cao HY, Li D, Wang YP, Lu HX, Sun J, Li HB. Cao HY, et al. Kaohsiung J Med Sci. 2020 May;36(5):354-362. doi: 10.1002/kjm2.12183. Epub 2020 Jan 13. Kaohsiung J Med Sci. 2020. PMID: 31930775 Free PMC article.
Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents.
Dalle Vedove C, Simon JC, Girolomoni G. Dalle Vedove C, et al. J Dtsch Dermatol Ges. 2012 Dec;10(12):889-97. doi: 10.1111/j.1610-0387.2012.08000.x. Epub 2012 Sep 3. J Dtsch Dermatol Ges. 2012. PMID: 22937775 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information